Feedback from the Phoenix Community: Our Visits with the FDA

Nathan Teuscher

We recently completed a week-long set of meetings with the FDA, where we met with over 300 FDA reviewers from 7 of the 11 FDA centers that use Phoenix. Here are a few topics that took center-stage during our visits: Q: How can we create Phoenix workflow templates that are reusable across different studies with […]

Read More
Topics: PK/PD Modeling & Simulation

Modeling PK/PD Systems with Distributed Delays

Suzanne Minton

Many biological systems exhibit time delays. For instance, there is a delay between the time that a virus infects a cell and the onset of viral production. Mathematical models that incorporate these temporal delays are often used to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of drugs. In this blog post, I’ll discuss some examples of biological systems […]

Read More
Topics: PK/PD Modeling & Simulation

Expanding the Use of Pharmacometrics in Japan with Yusuke Tanigawara

Suzanne Minton

Science is a global endeavor. Indeed, one of the most exciting things about drug development is working with scientists doing important research all over the globe. The use of modeling and simulation (M&S) to support drug development has been embraced by pharmaceutical researchers in some parts of the world and is still gaining traction in […]

Read More
Topics: PK/PD Modeling & Simulation

Nurturing the Pharmacometricians of the Future

Suzanne Minton

As a scientist, you always remember your first conference. The ability to share your research and learn from your peers is an invaluable part of any scientist’s training. That’s why I’m so proud that Certara helps support the travel and accommodation expenses for a selected number of students wishing to attend the Population Approach Group […]

Read More
Topics: PBPK Modeling & Simulation, PK/PD Modeling & Simulation

Using Pharmacokinetics to Assure Chemical Food Safety

Ronette Gehring

As a veterinarian, I’m responsible for the health and welfare of my animal patients. Sometimes, drugs are used to treat animals that are being raised for food (e.g., meat and milk). Therefore, tissue residues are a unique concern in veterinary medicine because indirect exposure to drugs and their metabolites through eating meat or milk could […]

Read More
Topics: PK/PD Modeling & Simulation

Navigating the Path for Pharmacokinetic CDISC Data Preparation

Maria Saluta

Data heterogeneity is a regulatory reviewer’s nightmare. Some sponsors talk about patient “gender” whereas others list the patient’s “sex.” What about date formats? Do you use the American-style month-day-year format or the European-style day-month-year? Inconsistent data presentation makes both collaborating on drug development projects and reviewing regulatory submissions more difficult. To address this challenge, the […]

Read More
Topics: PK/PD Modeling & Simulation

Modeling Delayed Outcomes in PK/PD Studies Using DDEs

Shuhua Hu

Delays are ubiquitous in pharmacokinetics (PK) and pharmacodynamics (PD) studies. Transit compartment models, described by systems of ordinary differential equations, have been widely used to describe delayed outcomes in PK and PD studies. The obvious disadvantage for this type of model is it requires manually finding proper values for the number of compartments. In addition, […]

Read More
Topics: PK/PD Modeling & Simulation

The Model-informed Precision Dosing Revolution Is Coming

Suzanne Minton

Modeling and simulation (M&S) has been widely accepted and adopted by biopharmaceutical companies and global regulatory agencies. However, its implementation in clinical care has been modest to date. Model-based approaches are essential to realize the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient. The […]

Read More
Topics: PBPK Modeling & Simulation, PK/PD Modeling & Simulation

Accessing Grid Computing from Your Desktop for NLME

Fred Soltanshahi

One of the most challenging aspects of population pharmacokinetic/pharmacodynamic (PK/PD) modeling is the lack of computing power required to solve complex models in a reasonable time frame to support rapid drug development decisions. The explosion of cloud computing resources has provided access to significant computing power to solve these complex models. However, accessing these cloud […]

Read More
Topics: PK/PD Modeling & Simulation

Prediction of Liver Volume; One Size Doesn’t Fit All!

Ben Small

When your physician writes you a prescription, they do so knowing that the dose prescribed will (on average) be safe and beneficial to you, but that it is likely certainly not optimal for you as an individual (as has been the topic of a previous blog post). The balance between absorption, distribution and elimination of […]

Read More
Topics: PBPK Modeling & Simulation, PK/PD Modeling & Simulation

How MBMA Can Help You Make Smarter Drug Development Decisions

Leon Bax

Successful drug development depends on making wise decisions about portfolios, clinical trials, marketing, etc. We’re continuously faced with the challenge of deciding whether to continue development or stop it. To support those decisions, we gather data, typically through clinical trials. We analyze the data from those clinical trials, and then we use these analyses to […]

Read More
Topics: Model-based Meta-analysis, PK/PD Modeling & Simulation

Leveraging Dissolution Testing to Meet Regulatory Guidelines

Jean-Michel Cardot

Dissolution testing is a standard tool in a formulation scientist’s arsenal. When companies make changes to drug products (particle size, excipients, manufacturing process, equipment, etc), health authorities often require comparing dissolution profiles to determine if the reference and test products are equivalent. Generic drug developers are also required to show bioequivalence between the branded drug […]

Read More
Topics: PK/PD Modeling & Simulation

Optimizing Drug Development Decisions: Looking Back at 2016

Suzanne Minton

Was it just me or did 2016 just seem to fly by? Reflecting on the events of the past year, I stumbled across this quote which seemed appropriate: There are years that ask questions and years that answer. [Zora Neale Hurston, Their Eyes Were Watching God] Our mission at Certara is helping our clients optimize […]

Read More
Topics: PK/PD Modeling & Simulation

PML School: Custom PK/PD Modeling Made Easy

Bernd Wendt

In our increasingly noise-filled world, sometimes, the most powerful insights come from listening. As the head of support at Certara, I get excited about listening to our clients’ pharmacokinetic/pharmacodynamic (PK/PD) modeling dilemmas and helping them solve them. And through listening to our users who call our support hotline, attend our training courses, or participate in […]

Read More
Topics: PK/PD Modeling & Simulation

The Ultimate Cheat Sheet on CDISC-SEND

Chris Lovejoy

On December 18, 2016, numerous regulatory agencies will require electronic submission of non-clinical data using CDISC’s standard format. What exactly are CDISC data standards and how will they impact drug developers? In this blog post, I will provide an overview of the CDISC SEND data standard, review some of the requirements for implementing SEND, and […]

Read More
Topics: PK/PD Modeling & Simulation

What’s New in Phoenix 7.0!

Maria Saluta

On September 14, Dr. Nathan Teuscher presented an informative webinar focused on new features and enhancements in Phoenix® 7.0, which was released on August 10. This blog post summarizes the topics discussed during the presentation. Nathan began his presentation with an overview of new features in Phoenix 7.0 including: A new graphics engine for high […]

Read More
Topics: PK/PD Modeling & Simulation

Quantitative Pharmacology Strategies for Pediatric Drug Development

Patrick Smith

Pediatric patients are not simply small adults. Children differ from adults in both disease pathophysiology and pharmacokinetics/pharmacodynamics (PK/PD). Yet historically, 80 percent of medicines used in children had little to no data guiding prescribers on proper use. In this blog post, I’ll discuss the challenges of developing drugs for children and explain how quantitative pharmacology […]

Read More
Topics: Clinical Pharmacology Strategy, PK/PD Modeling & Simulation

Arming Adherence-based Drug Development with Pharmacometrics

Jonathan Knights

The time is right to explore how sensor-enabled digital adherence monitoring systems can benefit patients, sponsors, and payers. Non-adherence to prescribed medications is a key issue facing our healthcare industry, costing the US healthcare economy between $100-300 billion annually, representing between 3-10% of total healthcare costs [1, 2]. Further, non-adherence also decreases our ability to […]

Read More
Topics: PK/PD Modeling & Simulation

How to Expedite FDA Approvals of Orphan Drugs

Thomas Peyret

350 million patients worldwide suffer from 7,000 rare diseases, yet only 300 of these diseases have approved treatments. This gap, impacting 95% of rare disease patients, represents a huge unmet medical need. Developing drugs for rare diseases poses a range of clinical, regulatory and commercial challenges. The small number of patients are difficult to identify […]

Read More
Topics: PK/PD Modeling & Simulation

Every Ending has a New Beginning

Nathan Teuscher

I created the Learn PK/PD site in May 2010 in response to a communication issue that I was facing in my daily work in the world of clinical pharmacology and pharmacokinetics. In my first post, I stated the reason for creating my blog and the website: My blog is dedicated to providing clear, concise, accurate, and […]

Read More
Topics: PK/PD Modeling & Simulation
Learn More
LinkedIn